PMID- 34399951
OWN - NLM
STAT- MEDLINE
DCOM- 20220331
LR  - 20240403
IS  - 1558-4410 (Electronic)
IS  - 0889-8529 (Print)
IS  - 0889-8529 (Linking)
VI  - 50
IP  - 3
DP  - 2021 Sep
TI  - Screening for Diabetes and Prediabetes.
PG  - 369-385
LID - S0889-8529(21)00036-0 [pii]
LID - 10.1016/j.ecl.2021.05.002 [doi]
AB  - Overt type 2 diabetes mellitus (T2DM) is preceded by prediabetes and latent 
      diabetes (lasts 9-12 years). Key dysglycemia screening tests are fasting plasma 
      glucose and hemoglobin A(1C). Screen-detected T2DM benefits from multifactorial 
      management of cardiovascular risk beyond glycemia. Prediabetes is best addressed 
      by lifestyle modification, with the goal of preventing T2DM. Although there is no 
      trial evidence of prediabetes/T2DM screening effectiveness, simulations suggest 
      that clinic-based opportunistic screening of high-risk individuals is 
      cost-effective. The most rigorous extant recommendations are those of the 
      American Diabetes Association and US Preventive Services Task Force, which advise 
      opportunistic 3-yearly screening.
CI  - Copyright (c) 2021 Elsevier Inc. All rights reserved.
FAU - Duan, Daisy
AU  - Duan D
AD  - Division of Endocrinology, Diabetes and Metabolism, Department of Medicine, Johns 
      Hopkins University School of Medicine, 5501 Hopkins Bayview Circle, Baltimore, MD 
      21224, USA.
FAU - Kengne, Andre P
AU  - Kengne AP
AD  - Non-Communicable Diseases Research Unit, South African Medical Research Council, 
      Francie van Zijl Drive Parowvallei, PO Box 19070, Tygerberg, Cape Town 7505, 
      South Africa.
FAU - Echouffo-Tcheugui, Justin B
AU  - Echouffo-Tcheugui JB
AD  - Division of Endocrinology, Diabetes and Metabolism, Department of Medicine, Johns 
      Hopkins University School of Medicine, 5501 Hopkins Bayview Circle, Baltimore, MD 
      21224, USA; Welch Prevention Center for Prevention, Epidemiology and Clinical 
      Research, Johns Hopkins University, Baltimore, MD, USA. Electronic address: 
      jechouf1@jhmi.edu.
LA  - eng
GR  - K23 HL153774/HL/NHLBI NIH HHS/United States
GR  - T32 HL110952/HL/NHLBI NIH HHS/United States
PT  - Journal Article
PT  - Research Support, N.I.H., Extramural
PT  - Review
DEP - 20210712
PL  - United States
TA  - Endocrinol Metab Clin North Am
JT  - Endocrinology and metabolism clinics of North America
JID - 8800104
RN  - 0 (Blood Glucose)
RN  - 0 (Glycated Hemoglobin A)
SB  - IM
MH  - Blood Glucose
MH  - *Diabetes Mellitus, Type 2/diagnosis/prevention & control
MH  - Glycated Hemoglobin/analysis
MH  - Humans
MH  - Mass Screening
MH  - *Prediabetic State/diagnosis/therapy
PMC - PMC8375583
MID - NIHMS1700534
OTO - NOTNLM
OT  - Cost-effectiveness
OT  - Diabetes
OT  - Effectiveness
OT  - Prediabetes
OT  - Screening
COIS- Disclosure The authors have no conflict of interest related to this article. Dr 
      J.B. Echouffo-Tcheugui was supported by NIH/NHLBI grant K23 HL153774. Dr D. Duan 
      was supported by NIH/NHLBI grant 5T32HL110952.
EDAT- 2021/08/18 06:00
MHDA- 2022/04/01 06:00
PMCR- 2022/09/01
CRDT- 2021/08/17 05:52
PHST- 2021/08/17 05:52 [entrez]
PHST- 2021/08/18 06:00 [pubmed]
PHST- 2022/04/01 06:00 [medline]
PHST- 2022/09/01 00:00 [pmc-release]
AID - S0889-8529(21)00036-0 [pii]
AID - 10.1016/j.ecl.2021.05.002 [doi]
PST - ppublish
SO  - Endocrinol Metab Clin North Am. 2021 Sep;50(3):369-385. doi: 
      10.1016/j.ecl.2021.05.002. Epub 2021 Jul 12.